CAJ | 학술논문

目的通过测定分化型甲状腺癌患者131I治疗后日尿排泄131I的活度值来估算患者体内残留的131I活度,并结合国家标准预测患者的出院时间.方法测量35例分化型甲状腺癌患者服131I后不同时间各次尿液的放射性活度,计算每位患者不同时间尿液排泄的总活度,进而估算患者体内残留的总活度.结果“清甲”及“清灶”治疗患者于服131I后第1d尿液内排泄的放射性活度分别为2401.5 MBq、4144.5MBq(占服131I总活度的64.9%、71%),而且“清甲”及“清灶”治疗后患者第1d体内残留131I活度分别为926.9MBq、1081.1MBq(占总131I活度的25.1%、17.2%),其后患者尿液内排泄的131I活度及患者体内残留131I活度下降幅度缓慢.20例“清甲”及15例“清灶”治疗的患者,达到国家标准的出院时间分别为3.1±2.2d、1.9±1.1d.结论甲状腺癌患者服用大剂量131I后短期内对周围环境和人有影响,所以患者必须入院并在规范的辐射防护病房隔离平均2-3d(48-72h)以上方可出院.
목적통과측정분화형갑상선암환자131I치료후일뇨배설131I적활도치래고산환자체내잔류적131I활도,병결합국가표준예측환자적출원시간.방법측량35례분화형갑상선암환자복131I후불동시간각차뇨액적방사성활도,계산매위환자불동시간뇨액배설적총활도,진이고산환자체내잔류적총활도.결과“청갑”급“청조”치료환자우복131I후제1d뇨액내배설적방사성활도분별위2401.5 MBq、4144.5MBq(점복131I총활도적64.9%、71%),이차“청갑”급“청조”치료후환자제1d체내잔류131I활도분별위926.9MBq、1081.1MBq(점총131I활도적25.1%、17.2%),기후환자뇨액내배설적131I활도급환자체내잔류131I활도하강폭도완만.20례“청갑”급15례“청조”치료적환자,체도국가표준적출원시간분별위3.1±2.2d、1.9±1.1d.결론갑상선암환자복용대제량131I후단기내대주위배경화인유영향,소이환자필수입원병재규범적복사방호병방격리평균2-3d(48-72h)이상방가출원.
Objective Through the determination of 131I posttreatment differentiated thyroid cancer patients' urine discharge 131I value in one day to estimate the residual 131I radioactivity in vivo, and combined with the national standard predict to forecast the patients' discharge time. Methods Measuring each of 35 differentiated thyroid cancer patient's urine radioactivity after take 131I, and calculating the total radioactivity in different time of each patient, and then estimating the total residual 131I radioactivity in patients. Results The 131I ablation therapy on remnant thyroid and 131I treatment on metastatic lesions in patients after the first day taking 131I, the urine discharge of radioactivity respectively was 2401.5MBq, 4144.5MBq(respectively accounts for 64.9% and 71% of the total taking 131I radioactivity), and the 131I ablation therapy on remnant thyroid and 131I treatment on metastatic lesions patients' residual 131I radioactivity in vivo respectively was 926.9MBq, 1081.1MBq(respectively accounts for 25.1% and 17.2% of total 131I radioactivity), followed by patients in the urine discharge of 131I radioactivity and the residual 131I radioactivity in vivo declines slowly. 20 cases of 131I ablation therapy on remnant thyroid and 15 cases of 131I treatment on metastatic lesions of patients, reach the national standard discharge time respectively was 3.1±2.2days and 1.9±1.1days. Conclusion The thyroid cancer patients who taking large doses of 131I will impact the surroundings and other people in a short term, so the patients must be hospitalized and isolated in the standard protective ward for average 2-3days(48-72h) before discharge.